Kymera Therapeutics (KYMR) closed at $121.52 on November 17, 2026, down 3.4% from the previous close, on volume of 799,284 shares (30-day average 926,828).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Ratio Call Spread 1 by 1.5 | 18-Dec-26135 : 185[1.5x] C | 1,300 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
Business Wire (Tue, 17-Nov 8:00 AM ET)
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
Globe Newswire (Wed, 28-Oct 4:01 PM ET)
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
PRNewswire (Mon, 12-Oct 9:31 AM ET)
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
PRNewswire (Wed, 30-Sep 8:59 AM ET)
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Market Chameleon (Thu, 25-Jun 6:33 AM ET)
Market Chameleon (Thu, 25-Jun 5:19 AM ET)
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Kymera Therapeutics trades on the NASDAQ stock market under the symbol KYMR.
As of November 18, 2026, KYMR stock price climbed to $122.36 with 238,118 million shares trading.
KYMR has a beta of 0.49, meaning it tends to be less sensitive to market movements. KYMR has a correlation of 0.01 to the broad based SPY ETF.
KYMR has a market cap of $10.45 billion. This is considered a Large Cap stock.
Last quarter Kymera Therapeutics reported $0 in Revenue and -$1.32 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.05.
In the last 3 years, KYMR traded as high as $142.92 and as low as $18.89.
The top ETF exchange traded funds that KYMR belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.
KYMR has outperformed the market in the last year with a return of +90.9%, while the SPY ETF gained +11.4%. In the last 3 month period, KYMR beat the market returning +0.8%, while SPY returned -4.8%. However, in the most recent 2 weeks KYMR has underperformed the stock market by returning -3.7%, while SPY returned -2.7%.
KYMR support price is $117.33 and resistance is $125.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYMR shares will trade within this expected range on the day.